T
Thomas A. Engler
Researcher at Eli Lilly and Company
Publications - 42
Citations - 1191
Thomas A. Engler is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Lewis acids and bases & Cycloaddition. The author has an hindex of 19, co-authored 42 publications receiving 1136 citations.
Papers
More filters
Journal ArticleDOI
Orally Bioavailable GSK-3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo
N.H. Kulkarni,Jude E. Onyia,Qingqiang Zeng,Xioayan Tian,Min Liu,David L. Halladay,Charles A. Frolik,Thomas A. Engler,Tao Wei,Aidas Kriauciunas,T. John Martin,Masahiko Sato,Henry Uhlman Bryant,Yanfei L. Ma +13 more
TL;DR: The effect of a small molecule GSK‐3 inhibitor was evaluated in pre‐osteoblasts and in osteopenic rats with concomitant increased bone mass and strength in rats.
Journal ArticleDOI
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
Thomas A. Engler,Henry,Sushant Malhotra,Brian Eugene Cunningham,Kelly Wayne Furness,Joseph T. Brozinick,Burkholder Timothy P,Michael P. Clay,Joshua Ryan Clayton,Clive Gideon Diefenbacher,Eric D. Hawkins,Philip W. Iversen,YiHong Burlingame Li,Terry D. Lindstrom,Angela Lynn Marquart,Mclean Johnathan Alexander,David Mendel,Elizabeth A. Misener,Daniel A. Briere,O'toole John Cunningham,Warren J. Porter,Queener S,Jon K. Reel,Owens Rebecca Anne,Richard A. Brier,Thomas E Eessalu,Wagner,Robert M. Campbell,Vaughn R +28 more
TL;DR: A series of potent and selective GSK3 inhibitors are discovered, 7-12 show oral activity in an in vivo model of type II diabetes, and 9 and 12 have desirable PK properties.
Journal ArticleDOI
Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Jennifer M. Atkinson,Kenneth B. Rank,Yi Zeng,Andrew Capen,Vipin Yadav,Jason Manro,Thomas A. Engler,Marcio Chedid +7 more
TL;DR: It is demonstrated that in vivo, LY2090314 elevates Axin2 gene expression after a single dose and produces tumor growth delay in A375 melanoma xenografts with repeat dosing, suggesting that the role of Wnt activators for the treatment of melanoma should be further explored.
Journal ArticleDOI